TABLE 2.

Escala Abreviada de Desarrollo, version 1^a (EAD-1) screener results at 20–30 mo of age among children postnatally infected with ZIKV^b (N = 60), Colombia, September-November 2017

Developmental domains	Without adverse neurologic, eye, or hearing outcomes (N = 51)	With adverse neurologic, eye, or hearing outcomes (N = 9c)
Gross motor	(N = 51)	(N = 9)
Alertd	0 (0%)	1 (11.1%)
Fine motor	(N = 51)	(N = 9)
Alertd	2 (3.9%)	1 (11.1%)
Hearing and language	(N = 47e)	(N = 9)
Alertd	6 (12.8%)	2 (22.2%)
Personal-social	(N = 50e)	(N = 9)
Alertd	3 (6.0%)	1 (11.1%)

^aThe EAD-1 is a standardised, validated developmental screening tool in Colombia.

^bParticipants were laboratory-confirmed with ZIKV infection by rRT-PCR within one week of symptom onset at 1–12 mo of age.

^cOne child with hypotonia also had a diagnosis of Down syndrome; the other child with hypotonia also had a diagnosis of sensorineural hearing loss; three children had unknown hearing loss; and four children had an abnormal eye finding. The child with abnormal retinal scarring also had reported congenital toxoplasmosis.

^dAn “alert” was based on cut points defined in the EAD-1 manual.

^eChildren whose domain score could not be calculated due to incorrect EAD-1 application were excluded.